Brigatinib in Treating Patients with Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Inclusion Criteria

• Patients must have a histologically confirmed diagnosis of relapsed or refractory ALCL with documented ALK positive status.
• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIL 2017 criteria.
• Ongoing toxicities from prior therapy must be resolved to =< grade 1 (with the exceptions of grade 2 peripheral neuropathy and/or alopecia). Patients with existing toxicities that are non-significant even though greater than grade 1 can be enrolled after discussion with the sponsor-investigator.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Prior use of ALK inhibitors aside from brigatinib is permitted but 8 patients enrolled need to be ALK inhibitor treatment naive.
• Patients with no archival tissue available must be agreeable to fresh biopsy at baseline.
• Patients with a known history of human immunodeficiency virus (HIV) are permitted provided the CD4 count >= 100 cells/uL and serum HIV viral load < 50 copies/mL. Patients must be on stable combination antiretroviral therapy at the time of treatment initiation.
• Absolute neutrophil count >= 1,000/mcL.
• Platelets >= 75,000/mcL (or 50,000/mcL if known bone marrow involvement by lymphoma).
• Total bilirubin within normal institutional limits (up to 2 x upper limit of normal [ULN] if history of Gilbert’s syndrome or known liver involvement).
• Aspartate aminotransferase/alanine aminotransferase (AST/ALT) (serum glutamic-oxaloacetic transaminase/serum glutamate pyruvate transaminase [SGOT/SGPT]) =< 2 times institutional normal limits.
• Creatinine within 1.5 x upper limit of normal institutional limits OR creatinine clearance >= 30 ml/min/1.73 m^2 for patients with creatinine levels above 1.5 x upper institutional normal.
• Serum lipase/amylase =< 1.5 x ULN.
• Hemoglobin >= 10 g/dL (can be transfused to achieve hemoglobin [Hgb] >= 10 g/dL).
• Ability to understand and willingness to sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) consent document. Legal appointed representative (LAR) are allowed to sign on patient’s behalf with proper documentation.
• Female patients who are postmenopausal for at least 1 year before the screening visit, or are surgically sterile. Female patients of childbearing potential should agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.
• Male patients, even if surgically sterilized (i.e., status postvasectomy), who agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug.

Exclusion Criteria

• History of another active primary malignancy within 2 years of initiating study treatment with the exception of non-melanomatous skin cancer, or any cancer that in the judgment of the investigator has been treated with curative intent and will not interfere with the study treatment plan and response assessment.
• Patients who have received chemotherapy or radiation therapy within 2 weeks of initiating study treatment.
• Patients may not be receiving any other investigational agents.
• Patients who have symptomatic central nervous system (CNS) metastases (parenchymal or leptomeningeal) at screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days prior to randomization. * Note: If a patient has worsening neurological symptoms or signs due to CNS metastasis, the patient needs to complete local therapy and be neurologically stable (with no requirement for an increasing dose of corticosteroids or use of anticonvulsants) for 7 days prior to enrollment.
• History of allergic reactions attributed to other ALK inhibitors.
• History of interstitial pneumonitis or drug-related pneumonitis.
• Impaired gastrointestinal function that may affect oral absorption of brigatinib.
• Patients with known active hepatitis B or hepatitis C (defined as having a detectable hepatitis B or C viral load).
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Physician’s discretion may be exercised to determine eligibility for patients with psychiatric illness/social situations.
• Pregnant or breast-feeding.